Conversely, the efficacy of combining ICIs with platinum-doublet chemotherapy, which is the standard first-line treatment for NSCLC lacking identifiable driver mutations, remains debatable. This study is the first to report on the efficacy of ABCP therapy in EGFR-mutant NSCLC after EGFR-TKI treatment, with a particular focus on the differences in effect between the EGFR L858R and EGFR Ex19del subtypes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.